Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

  • Filters activated: Toxicology. Clear all to show 76 items.
1.

Development of new agents for peripheral T-cell lymphoma.

Ito Y, Makita S, Tobinai K.

Expert Opin Biol Ther. 2019 Mar;19(3):197-209. doi: 10.1080/14712598.2019.1572746. Epub 2019 Jan 29. Review.

PMID:
30658046
2.

Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases.

Erra M, Taltavull J, Bernal FJ, Caturla JF, Carrascal M, Pagès L, Mir M, Espinosa S, Gràcia J, Domínguez M, Sabaté M, Paris S, Maldonado M, Hernández B, Bravo M, Calama E, Miralpeix M, Lehner MD, Calbet M.

J Med Chem. 2018 Nov 8;61(21):9551-9567. doi: 10.1021/acs.jmedchem.8b00873. Epub 2018 Oct 29.

PMID:
30351000
3.

Duvelisib in haematological malignancies.

Das M.

Lancet Oncol. 2018 Nov;19(11):e586. doi: 10.1016/S1470-2045(18)30756-3. Epub 2018 Oct 11. No abstract available.

PMID:
30318318
4.

The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.

Faia K, White K, Murphy E, Proctor J, Pink M, Kosmider N, McGovern K, Kutok J.

PLoS One. 2018 Aug 1;13(8):e0200725. doi: 10.1371/journal.pone.0200725. eCollection 2018.

5.

Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.

Flinn IW, Patel M, Oki Y, Horwitz S, Foss FF, Allen K, Douglas M, Stern H, Sweeney J, Kharidia J, Kelly P, Kelly VM, Kahl B.

Am J Hematol. 2018 Nov;93(11):1311-1317. doi: 10.1002/ajh.25228. Epub 2018 Aug 31.

6.

Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.

Ali AY, Wu X, Eissa N, Hou S, Ghia JE, Murooka TT, Banerji V, Johnston JB, Lin F, Gibson SB, Marshall AJ.

Leukemia. 2018 Sep;32(9):1958-1969. doi: 10.1038/s41375-018-0012-5. Epub 2018 Jan 31.

7.

Transformation of chronic lymphocytic leukemia into B-cell acute lymphoblastic leukemia.

Yun S, Zhang L, Patel MR, Knepper TC, Chavez JC, Pinilla-Ibarz J.

Blood. 2018 Mar 15;131(11):1258-1261. doi: 10.1182/blood-2017-11-819276. Epub 2018 Feb 5. No abstract available.

8.

Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.

Horwitz SM, Koch R, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM.

Blood. 2018 Feb 22;131(8):888-898. doi: 10.1182/blood-2017-08-802470. Epub 2017 Dec 12.

9.

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

Flinn IW, O'Brien S, Kahl B, Patel M, Oki Y, Foss FF, Porcu P, Jones J, Burger JA, Jain N, Kelly VM, Allen K, Douglas M, Sweeney J, Kelly P, Horwitz S.

Blood. 2018 Feb 22;131(8):877-887. doi: 10.1182/blood-2017-05-786566. Epub 2017 Nov 30.

10.

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

Lampson BL, Brown JR.

Expert Opin Investig Drugs. 2017 Nov;26(11):1267-1279. doi: 10.1080/13543784.2017.1384815. Epub 2017 Oct 6. Review.

11.

Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.

Schaffer M, Chaturvedi S, Davis C, Aquino R, Stepanchick E, Versele M, Liu Y, Yang J, Lu R, Balasubramanian S.

Leuk Lymphoma. 2018 Apr;59(4):931-940. doi: 10.1080/10428194.2017.1349899. Epub 2017 Jul 28.

PMID:
28750570
12.

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.

Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM.

Oncotarget. 2017 Apr 4;8(14):23213-23227. doi: 10.18632/oncotarget.15542.

13.

Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.

Vangapandu HV, Jain N, Gandhi V.

Expert Opin Investig Drugs. 2017 May;26(5):625-632. doi: 10.1080/13543784.2017.1312338. Epub 2017 Apr 13. Review.

14.

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.

Piddock RE, Loughran N, Marlein CR, Robinson SD, Edwards DR, Yu S, Pillinger GE, Zhou Z, Zaitseva L, Auger MJ, Rushworth SA, Bowles KM.

Blood Cancer J. 2017 Mar 10;7(3):e539. doi: 10.1038/bcj.2017.16.

15.

Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.

Compagno M, Wang Q, Pighi C, Cheong TC, Meng FL, Poggio T, Yeap LS, Karaca E, Blasco RB, Langellotto F, Ambrogio C, Voena C, Wiestner A, Kasar SN, Brown JR, Sun J, Wu CJ, Gostissa M, Alt FW, Chiarle R.

Nature. 2017 Feb 23;542(7642):489-493. doi: 10.1038/nature21406. Epub 2017 Feb 15.

16.

Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia.

Orioli L, Sarti K, Van Den Neste E, Maiter D.

Ann Hematol. 2017 Apr;96(4):685-686. doi: 10.1007/s00277-017-2928-7. Epub 2017 Feb 1. No abstract available.

PMID:
28150013
17.

Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.

Willemsen-Seegers N, Uitdehaag JCM, Prinsen MBW, de Vetter JRF, de Man J, Sawa M, Kawase Y, Buijsman RC, Zaman GJR.

J Mol Biol. 2017 Feb 17;429(4):574-586. doi: 10.1016/j.jmb.2016.12.019. Epub 2016 Dec 30.

PMID:
28043854
18.

Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).

Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG, O'Brien S, Jain N, Stern HM, Gandhi V.

Leukemia. 2017 Sep;31(9):1872-1881. doi: 10.1038/leu.2016.382. Epub 2016 Dec 26.

19.

Novel Drugs in Follicular Lymphoma.

Anastasia A, Rossi G.

Mediterr J Hematol Infect Dis. 2016 Nov 1;8(1):e2016061. eCollection 2016. Review.

20.

New drugs for follicular lymphoma.

Sorigue M, Ribera JM, Motlló C, Sancho JM.

Leuk Res. 2016 Oct;49:38-46. doi: 10.1016/j.leukres.2016.08.004. Epub 2016 Aug 10. Review.

PMID:
27541051

Supplemental Content

Loading ...
Support Center